Articles producció científica> Medicina i Cirurgia

D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis

  • Identification data

    Identifier: imarina:5651864
    Handle: https://hdl.handle.net/20.500.11797/imarina5651864
    Authors:
    Jara-Palomares LSolier-Lopez AElias-Hernandez TAsensio-Cruz MBlasco-Esquivias ISanchez-Lopez Vde la Borbolla MArellano-Orden ESuarez-Valdivia LMarin-Romero SMarin-Barrera LRuiz-Garcia AMontero-Romero ENavarro-Herrero SLopez-Campos JSerrano-Gotarredona MPraena-Fernandez JSanchez-Diaz JOtero-Candelera R
    Abstract:
    © 2018, Cancer Research UK. Background: Optimal duration of anticoagulation for cancer-associated thrombosis (CAT) remains unclear. This study assessed D-dimer (DD) and high-sensitivity C-reactive protein (hs-CRP) levels after the withdrawal of anticoagulation treatment to predict the risk of venous thromboembolism (VTE) recurrence among patients with CAT. Methods: Prospective, multicentre study to evaluate CAT with ≥3 months of anticoagulation that was subsequently discontinued. Blood samples were taken when patients stopped the anticoagulation and 21 days later to determine the DD and hs-CRP levels. All patients were followed up for 6 months to detect VTE recurrence. Results: Between 2013 and 2015, 325 patients were evaluated and 114 patients were ultimately enrolled in the study. The mean age was 62 ± 14 years and nearly 40% had metastasis. Ten patients developed VTE recurrence within 6 months (8.8%, 95% confidence interval [CI]: 4.3–15.5%). The DD and hs-CRP levels after 21 days were associated with VTE recurrence. The subdistribution hazard ratios were 9.82 for hs-CRP (95% CI: 19–52) and 5.81 for DD (95% CI: 1.1–31.7). Conclusions: This study identified that hs-CRP and DD were potential biomarkers of VTE recurrence after discontinuation of anticoagulation in CAT. A risk-adapted strategy could identify low-risk patients who may benefit from discontinuation of anticoagulation.

  • Others:

    Author, as appears in the article.: Jara-Palomares L; Solier-Lopez A; Elias-Hernandez T; Asensio-Cruz M; Blasco-Esquivias I; Sanchez-Lopez V; de la Borbolla M; Arellano-Orden E; Suarez-Valdivia L; Marin-Romero S; Marin-Barrera L; Ruiz-Garcia A; Montero-Romero E; Navarro-Herrero S; Lopez-Campos J; Serrano-Gotarredona M; Praena-Fernandez J; Sanchez-Diaz J; Otero-Candelera R
    Department: Medicina i Cirurgia
    URV's Author/s: Porras Ledantes, Jose Antonio
    Keywords: Tinzaparin Therapy Risk Pulmonary-embolism Prophylaxis Prevention Molecular-weight heparin Duration Disease Deep-vein thrombosis
    Abstract: © 2018, Cancer Research UK. Background: Optimal duration of anticoagulation for cancer-associated thrombosis (CAT) remains unclear. This study assessed D-dimer (DD) and high-sensitivity C-reactive protein (hs-CRP) levels after the withdrawal of anticoagulation treatment to predict the risk of venous thromboembolism (VTE) recurrence among patients with CAT. Methods: Prospective, multicentre study to evaluate CAT with ≥3 months of anticoagulation that was subsequently discontinued. Blood samples were taken when patients stopped the anticoagulation and 21 days later to determine the DD and hs-CRP levels. All patients were followed up for 6 months to detect VTE recurrence. Results: Between 2013 and 2015, 325 patients were evaluated and 114 patients were ultimately enrolled in the study. The mean age was 62 ± 14 years and nearly 40% had metastasis. Ten patients developed VTE recurrence within 6 months (8.8%, 95% confidence interval [CI]: 4.3–15.5%). The DD and hs-CRP levels after 21 days were associated with VTE recurrence. The subdistribution hazard ratios were 9.82 for hs-CRP (95% CI: 19–52) and 5.81 for DD (95% CI: 1.1–31.7). Conclusions: This study identified that hs-CRP and DD were potential biomarkers of VTE recurrence after discontinuation of anticoagulation in CAT. A risk-adapted strategy could identify low-risk patients who may benefit from discontinuation of anticoagulation.
    Thematic Areas: Saúde coletiva Química Oncology Odontología Medicina veterinaria Medicina iii Medicina ii Medicina i Materiais General medicine Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Cancer research Biotecnología
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 00070920
    Author's mail: joseantonio.porras@urv.cat
    Author identifier: 0000-0001-6418-1822
    Record's date: 2024-09-07
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.nature.com/articles/s41416-018-0269-5
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: British Journal Of Cancer. 119 (8): 915-921
    APA: Jara-Palomares L; Solier-Lopez A; Elias-Hernandez T; Asensio-Cruz M; Blasco-Esquivias I; Sanchez-Lopez V; de la Borbolla M; Arellano-Orden E; Suarez-V (2018). D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis. British Journal Of Cancer, 119(8), 915-921. DOI: 10.1038/s41416-018-0269-5
    Article's DOI: 10.1038/s41416-018-0269-5
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2018
    Publication Type: Journal Publications

  • Keywords:

    Cancer Research,Oncology
    Tinzaparin
    Therapy
    Risk
    Pulmonary-embolism
    Prophylaxis
    Prevention
    Molecular-weight heparin
    Duration
    Disease
    Deep-vein thrombosis
    Saúde coletiva
    Química
    Oncology
    Odontología
    Medicina veterinaria
    Medicina iii
    Medicina ii
    Medicina i
    Materiais
    General medicine
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Cancer research
    Biotecnología

  • Documents:

  • Cerca a google

    Search to google scholar